Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The last week of April each year is Immunization Week.

Whilst many diseases can be prevented by vaccination, there is currently no licensed vaccine for malaria – a disease that affects many millions of people each year with a high mortality rate. NDM spoke to Professor Adrian Hill, Director of the Jenner Institute and a leader in malaria vaccine development, about his aspirations to develop a highly effective licensed vaccine that could eventually help eradicate malaria.

Read more

NDM spoke to Professor Sarah GilbertProfessor of Vaccinology and Programme leader in Human Influenza Vaccines at the Jenner Institute, about her research developing a ‘universal flu vaccine’ and the importance of vaccinating against flu.

Read more

Similar stories

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Why we must expand newborn screening

General Research

Professor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.

New method for cost-effective genome-wide DNA methylation analysis

General Research

Ludwig Cancer Research team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.

Azithromycin not effective against COVID-19, trial confirms

Clinical Trials General Research

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.